Parc de Biocitech, Romainville, May 20, 2008 – Mutabilis, www.mutabilis.com, a biopharma company specializing in the discovery and development of innovative anti-infective therapies, today announced that Stefan Fischer has joined the firm as Chief Executive Officer (CEO).
Prior to joining Mutabilis, Stefan Fischer acquired significant experience in the UK as CEO at Lorantis, where he efficiently led a wide-ranging corporate refocusing operation, and then at Capsant, where he managed the company's overall strategy and contributed to its excellent performance.
He had previously spent 10 years with Roche in Germany managing a number of product portfolios in the AIDS, cancer and obesity fields, before taking up a Market Analyst post where he coordinated the business and sales launches for a range of products on the German market. He then moved to the Licensing Department as Global Alliance Director, where he built and managed teams for assessing product in-licensing and acquisition opportunities.
Stefan Fischer holds an MSc in Chemistry from the University of Bochum.
"I am really looking forward to working with Stefan", emphasized Sonia Escaich, PhD., CSO and a Mutabilis co-founder. "In view of his international experience and his expertise in our business sector, Stefan has the perfect profile for giving new momentum to the company".
"I am delighted to be joining the Mutabilis team, which is widely acknowledged for its expertise and innovative approach in the field of antibiotic resistance – a major issue for the healthcare industry", commented Stefan Fischer, President of the Executive Board and CEO of Mutabilis.
+ 33 6 64 18 99 59